MediGene AG, the biotechnology company which has recently re-focused its strategy on oncology and immunology, has appointed Axel Mescheder as its new executive board member in charge of research and development. Dr Mescheder, who was head of clinical research and development at MediGene, is replacing Ulrich Delvos, who is resigning from the firm.
Source:
MediGene press release 21 May 2008
Copyright Evernow Publishing 2008